Palisade Bio, Inc. (PALI)
Palisade Bio, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Palisade Bio, Inc. (PALI) is a Biotechnology company based in US with a market capitalization of $333.3M. Free cash flow was negative at -$10.8M. This page tracks PALI's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 8 employees · IPO Mar 30, 2007
Valuation
Valuation & price
$1.83as of May 17, 2026· -34.6% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
2.58
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$333.3M
Market cap
—
Revenue growth (YoY)
100.0%
Gross margin
-$10.8M
Free cash flow (USD)
-$133.3M
Net debt
Net cash position
3831.5%
Share dilution
2/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Value screen
Graham defensive-investor tests
3
Insider buys · 90 days
2
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 12, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- Insider buyJul 10, 2026Filing
Insider Buy $89KBaltera Robert Jr. · Director · $88.7K
- Insider sellJul 8, 2026Filing
Insider Sell $107KJones Mitchell Lawrence · Chief Medical Officer · $106.5K
- Insider buyJul 8, 2026Filing
Insider Buy $102KBaltera Robert Jr. · Director · $102.1K
- Insider sellJul 8, 2026Filing
Insider Sell $303KFinley John David · Director, CEO, CFO · $303.3K
- Insider buyJul 6, 2026Filing
Insider Buy $59KBaltera Robert Jr. · Director · $59.4K
- 8-K eventJun 11, 2026Filing
Equity Incentive Plan Amended
- Quarterly reportMay 12, 2026Filing
10-Q Filed
- 8-K eventMay 12, 2026Filing
Earnings Release
- FinancingMay 12, 2026Filing
Securities Registration
- 8-K eventApr 2, 2026Filing
Stock Issuance
Questions
Frequently asked questions
What is Palisade Bio, Inc.'s market cap?
Palisade Bio, Inc. (PALI) has a market capitalization of $333.3M.
What is PALI's P/E ratio?
A meaningful P/E ratio is not available for PALI — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is PALI's price-to-book (P/B) ratio?
PALI trades at 2.58 times book value per share.
Are insiders buying PALI stock?
Yes — SEC Form 4 filings show 3 open-market insider buys and 2 sells at Palisade Bio, Inc. in the last 90 days.
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.